Abstract:Non-alcoholic fatty liver disease (NAFLD) was recently renamed to metabolic dysfunctionassociated liver disease (MASLD) to emphasize the metabolic dysfunctions that most often accompany its manifestation [1]. MASLD covers a spectrum of liver diseases, ranging from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), a clinical condition characterized by steatosis, hepatocellular injury, and inflammation with or without fibrosis [1]. MASH can further progress to cirrhosis and, in a certain fraction of patients, to hepatocellular carcinoma (HCC) [2]. Multiple factors sustain the transition from MASLD to MASH and its advanced stages, but emerging evidence indicates chronic inflammation as the driving force underlying the process [2]. Therefore, understanding the cellular and molecular mechanisms responsible for inflammatory responses may lay the foundations for treatments to counteract MASH and its complications.In this article collection, the authors summarized the recent advances concerning the modulation of inflammatory responses associated with MASH.Growing evidence indicates that hepatokines mediate key steps of MASLD/MASH [3,4]. Foglia and colleagues addressed this issue by exploring the pathological implications of the histidine-rich glycoprotein (HRG) in MASH-related carcinogenesis. HGR is a glycoprotein which interacts with several molecules and modulates essential biological processes [5]. The authors found that HRG levels increase in parallel with the disease severity, and the HRG genetic deletion protects mice from MASH-related HCC by a ecting multiple pathways.Hepatokines, like other molecules, mediate biological e ects by triggering specific receptors, which transduce complex signals underlying MASH [6]. Apostolo et al. reviewed the implications of TAM receptors (Tyro 3, Axl and MerTK) in the transition from MASLD/MASH to HCC. The authors described that TAM receptors, along with the common ligand Growth Arrest Specific (GAS) 6, support the development of MASH. Indeed, the Gas6/TAM axis modulates inflammatory responses and stimulates the activation, survival and proliferation of hepatic stellate cells (HSCs). The TAM/Gas6 system also promotes the induction of signalling pathways involved in tumour growth and dissemination. Furthermore, it may lead to resistance to sorafenib in HCC cells, so much so that pharmacological targeting of Axl restores the cell sensitivity to sorafenib. Grøndal et al. further investigates TAM receptors in MASH, observing that the levels of the soluble form of Axl (sAxl) increase in preclinical models of MASLD/MASH, in parallel with the induction of inflammatory responses, suggesting that sAxl may represent an early marker for MASLD/MASH. The authors also described the mechanistic involvement of Axl in MASLD/MASH, reporting that its pharmacological inhibition reduces steatosis, inflammation and fibrosis. The authors also investigated the mechanisms by which Axl inhibition ameliorates MASLD/MASH, describing that Axl inhibition has an immunomodulatory action by lowering the hepatic expression of pro-inflammatory mediators along with the abundance of NK cells and various dendritic cell (DC) subsets.Besides TAM, additional families of receptors contribute to inflammatory responses like protease-activated receptors (PARs). PARs are the substrate of multiple proteases capable of cutting the extracellular N-terminus sequence, which becomes the agonist of PARs themselves [7]. Villano and Pontisso reviewed the current available data on PAR2 and its implications in MASLD/MASH. PAR2 activation drives MASLD development by impairing the insulin pathway and causing insulin resistance (IR) and liver steatosis. PAR2 also promotes the transition from MASLD to MASH by activating inflammatory pathways and HSCs. PAR2 activation also supports cell transformation by inhibiting the AMPK-mediated autophagy and promotes tumour growth and metastatization via the PI3K/AKT signaling pathway. Consistently, PAR2 antagonists inhibit liver injury, inflammation and fibrosis in the experimental MASH.MASH-associated inflammatory responses involve multiple immune cell subsets belonging to the innate and adaptive immunity branches, such as macrophages (MFs), dendritic cells (DCs), NK/NKT cells and T/B-lymphocytes [8][9][10]. These cells influence the hepatic microenvironment by secreting multiple cyto/chemokines and mediating the disease progression [11]. Saueret al. analyzed this issue by investigating the e ects of the secretome derived from di erentially polarized human primary monocytes/macrophages and NK cells in activating HSCs. The authors found that "classical" stimuli for MFs (TNF-α, IL-4 and IL13) and NK cells (IL-15) fail in activating HSCs in vitro. Conversely, the hyperactivation of MFs and NK cells with the phorbol 12-myristate 13-acetate (PMA), a non-specific pro-inflammatory agent, promotes a strong activation of HSCs. O -Abstract Truncated-

Impaired postprandial GLP-2 response enhances endotoxemia, systemic inflammation, and kidney injury in metabolic dysfunction-associated steatohepatitis (MASH): effect of phospholipid curcumin meriva

Glycogen synthase kinase 3 activity enhances liver inflammation in MASH

Glucagon-Like Peptide-2 Modulates Enteric Paneth Cells Immune Response and Alleviates Gut Inflammation During Intravenous Fluid Infusion in Mice With a Central Catheter

The role of glucagon‐like peptide‐1 receptor agonists in metabolic dysfunction‐associated steatohepatitis

Curcumin Supplementation (Meriva®) Modulates Inflammation, Lipid Peroxidation and Gut Microbiota Composition in Chronic Kidney Disease

GSDME promotes MASLD by regulating pyroptosis, Drp1 citrullination-dependent mitochondrial dynamic, and energy balance in intestine and liver

Changes in intestinal permeability and gut microbiota following diet-induced weight loss in patients with metabolic dysfunction-associated steatohepatitis and liver fibrosis

Circulating Neutrophil Profiles Undergo a Dynamic Shift during Metabolic Dysfunction-Associated Steatohepatitis (MASH) Progression

Genetic Evidence for GLP‐1 and GIP Receptors as Targets for Treatment and Prevention of MASLD/MASH

Thyroid hormone receptor-beta agonist HSK31679 alleviates MASLD by modulating gut microbial sphingolipids

Incretin-based investigational therapies for the treatment of MASLD/MASH

Diabetes as a risk factor for MASH progression

Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH

An Integrated Analysis of the Role of Gut Microbiome-Associated Metabolites in the Detection of MASH-Related Cirrhosis

Enhanced venous thrombosis and hypercoagulability in murine and human metabolic dysfunction-associated steatohepatitis

The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Current Progress and Challenges in the Development of Pharmacotherapy for Metabolic Dysfunction‐Associated Steatohepatitis

Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: Systematic review and network meta-analysis

Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study

S1768 The Efficacy of GLP-1 Agonists in the Management of MASH in an Appalachian Cohort

Editorial: Inflammatory responses on the road from NASH to HCC: pathogenic mechanisms and possible therapeutic strategies